Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab Plus Chemotherapy in Advanced Malignant Pleural Mesothelioma
NCT07885319Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Nov 2026
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in malignant pleural mesothelioma (MPM), sponsored by Ruijin Hospital. Primary endpoints: Dose-Limiting Toxicities at Day 28 and Objective Response Rate up to 24 months. Started Nov 2026; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT07885319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07885319.